Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis.

Cappelli LC, Thomas MA, Bingham CO 3rd, Shah AA, Darrah E.

Immunol Rev. 2020 Jan 13. doi: 10.1111/imr.12832. [Epub ahead of print] Review.

PMID:
31930524
2.

Sonographic Findings in Inflammatory Arthritis Secondary to Immune Checkpoint Inhibition: A Case Series.

Albayda J, Dein E, Shah AA, Bingham CO 3rd, Cappelli L.

ACR Open Rheumatol. 2019 Jun 12;1(5):303-307. doi: 10.1002/acr2.1026. eCollection 2019 Jul.

3.

Patient-Reported Outcomes in Adult Idiopathic Inflammatory Myopathies.

DiRenzo D, Bingham CO 3rd, Mecoli CA.

Curr Rheumatol Rep. 2019 Nov 19;21(11):62. doi: 10.1007/s11926-019-0862-5. Review.

PMID:
31741079
4.

Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence: qualitative results.

Bartlett SJ, De Leon E, Orbai AM, Haque UJ, Manno RL, Ruffing V, Butanis A, Duncan T, Jones MR, Leong A, Perin J, Smith KC, Bingham CO.

Rheumatology (Oxford). 2019 Oct 30. pii: kez506. doi: 10.1093/rheumatology/kez506. [Epub ahead of print]

PMID:
31665477
5.

What does the patient global health assessment in RA really tell us? Contribution of specific dimensions of health-related quality of life.

Craig ET, Perin J, Zeger S, Curtis JR, Bykerk VP, Bingham CO, Bartlett SJ.

Arthritis Care Res (Hoboken). 2019 Sep 24. doi: 10.1002/acr.24073. [Epub ahead of print]

PMID:
31549772
6.

The Relationship Between Autonomic Dysfunction of the Gastrointestinal Tract and Emotional Distress in Patients With Systemic Sclerosis.

DiRenzo D, Russell J, Bingham CO 3rd, McMahan Z.

J Clin Rheumatol. 2019 Sep 12. doi: 10.1097/RHU.0000000000001144. [Epub ahead of print]

PMID:
31524844
7.

Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.

Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP.

J Rheumatol. 2019 Sep 15. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print]

PMID:
31523049
8.

Statin Use and Knee Osteoarthritis Outcome Measures according to the Presence of Heberden Nodes: Results from the Osteoarthritis Initiative.

Haj-Mirzaian A, Mohajer B, Guermazi A, Conaghan PG, Lima JAC, Blaha MJ, Bingham CO, Roemer FW, Cao X, Demehri S.

Radiology. 2019 Nov;293(2):396-404. doi: 10.1148/radiol.2019190557. Epub 2019 Sep 10.

PMID:
31502936
9.

The International RA BIODAM Cohort for Validation of Soluble Biomarkers in Rheumatoid Arthritis: Cohort Description.

Maksymowych WP, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Allaart R, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewé R.

J Rheumatol. 2019 Sep 1. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print]

PMID:
31474600
10.

Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change.

Mahmoud TG, Huang J, Frits M, Iannaccone C, Bykerk V, Bingham CO 3rd, Weinblatt M, Shadick NA.

J Rheumatol. 2019 Jun 15. pii: jrheum.181160. doi: 10.3899/jrheum.181160. [Epub ahead of print]

PMID:
31203222
11.

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Naidoo J, Zhang J, Lipson EJ, Forde PM, Suresh K, Moseley KF, Mehta S, Kwatra SG, Parian AM, Kim AK, Probasco JC, Rouf R, Thorne JE, Shanbhag S, Riemer J, Shah AA, Pardoll DM, Bingham CO, Brahmer JR, Cappelli LC.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268.

PMID:
31200355
12.

Soluble Markers of Antibody Secreting Cell Function as Predictors of Infection Risk in Rheumatoid Arthritis.

Gutierrez MJ, Desiderio SV, Wang NY, Darrah E, Cappelli L, Nino G, Jones M, Bingham CO 3rd.

J Immunol Res. 2019 Apr 28;2019:3658215. doi: 10.1155/2019/3658215. eCollection 2019.

13.

Delphi panelists for a core outcome set project suggested both new and existing dissemination strategies that were feasibly implemented by a research infrastructure project.

Akinremi A, Turnbull AE, Chessare CM, Bingham CO 3rd, Needham DM, Dinglas VD.

J Clin Epidemiol. 2019 Oct;114:104-107. doi: 10.1016/j.jclinepi.2019.05.026. Epub 2019 Jun 5. No abstract available.

PMID:
31173895
14.

Correction to: Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.

Bingham CO 3rd, Gaich CL, DeLozier AM, Engstrom KD, Naegeli AN, de Bono S, Banerjee P, Taylor PC.

Trials. 2019 Jun 4;20(1):322. doi: 10.1186/s13063-019-3463-8.

15.

Association of Pain Centralization and Patient-Reported Pain in Active Rheumatoid Arthritis.

Heisler AC, Song J, Dunlop DD, Wohlfahrt A, Bingham CO 3rd, Bolster MB, Clauw DJ, Marder W, Phillips K, Neogi T, Lee YC.

Arthritis Care Res (Hoboken). 2019 Jun 4. doi: 10.1002/acr.23994. [Epub ahead of print]

PMID:
31162824
16.

Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.

Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, Kartman CE.

Arthritis Res Ther. 2019 Apr 18;21(1):102. doi: 10.1186/s13075-019-1883-1.

17.

Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.

Bingham CO 3rd, Gaich CL, DeLozier AM, Engstrom KD, Naegeli AN, de Bono S, Banerjee P, Taylor PC.

Trials. 2019 Mar 22;20(1):182. doi: 10.1186/s13063-019-3272-0. Erratum in: Trials. 2019 Jun 4;20(1):322.

18.

Sonographic findings from inflammatory arthritis due to antisynthetase syndrome.

Miller JB, Danoff SK, Bingham CO 3rd, Paik JJ, Mecoli CA, Tiniakou E, Christopher-Stine L, Albayda J.

Clin Rheumatol. 2019 May;38(5):1477-1483. doi: 10.1007/s10067-019-04471-y. Epub 2019 Feb 27.

PMID:
30810913
19.

Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion.

Andersen KM, Kelly A, Lyddiatt A, Bingham CO 3rd, Bykerk VP, Batterman A, Westreich J, Jones MK, Cross M, Brooks PM, March L, Shea B, Tugwell P, Simon LS, Christensen R, Bartlett SJ.

J Rheumatol. 2019 Sep;46(9):1168-1172. doi: 10.3899/jrheum.181185. Epub 2019 Feb 15.

PMID:
30770516
20.

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.

Boers M, Beaton DE, Shea BJ, Maxwell LJ, Bartlett SJ, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1021-1027. doi: 10.3899/jrheum.181096. Epub 2019 Feb 15.

PMID:
30770515
21.

Advancing Stiffness Measurement in Rheumatic Disease: Report from the Stiffness Special Interest Group at OMERACT 2018.

Craig ET, Orbai AM, Mackie S, Bartlett SJ, Bingham CO 3rd, Goodman S, Hill C, Holt R, Leong A, Karyekar C, Leung YY, Richards P, Halls S.

J Rheumatol. 2019 Oct;46(10):1374-1378. doi: 10.3899/jrheum.181074. Epub 2019 Feb 15.

PMID:
30770511
22.

OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies.

Regardt M, Mecoli CA, Park JK, de Groot I, Sarver C, Needham M, de Visser M, Shea B, Bingham CO 3rd, Lundberg IE, Song YW, Christopher-Stine L, Alexanderson H.

J Rheumatol. 2019 Oct;46(10):1351-1354. doi: 10.3899/jrheum.181065. Epub 2019 Feb 15.

PMID:
30770504
23.

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.

Maxwell LJ, Beaton DE, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit M, Gossec L, March L, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1014-1020. doi: 10.3899/jrheum.181097. Epub 2019 Feb 15.

PMID:
30770502
24.

Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop.

Morgan EM, Munro JE, Horonjeff J, Horgan B, Shea B, Feldman BM, Clairman H, Bingham CO 3rd, Thornhill S, Strand V, Alongi A, Magni-Manzoni S, van Rossum MAJ, Vesely R, Vojinovic J, Brunner HI, Harris JG, Horton DB, Lovell DJ, Mannion M, Rahimi H, Ravelli A, Ringold S, Ruperto N, Schrandt MS, Shenoi S, Shiff NJ, Toupin-April K, Tzaribachev N, Weiss P, Consolaro A.

J Rheumatol. 2019 Aug;46(8):1006-1013. doi: 10.3899/jrheum.181088. Epub 2019 Feb 15.

PMID:
30770499
25.

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.

Beaton DE, Maxwell LJ, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1028-1035. doi: 10.3899/jrheum.181218. Epub 2019 Feb 1.

PMID:
30709952
26.

Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?

Kostine M, Cappelli LC, Calabrese C, Calabrese LH, Bingham CO 3rd, Richez C, Gottenberg JE, Lambotte O.

Ann Rheum Dis. 2019 Jun;78(6):860-862. doi: 10.1136/annrheumdis-2018-214748. Epub 2019 Jan 18. No abstract available.

PMID:
30659050
27.

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials.

Andersen KM, Cheah JTL, March L, Bartlett SJ, Beaton D, Bingham CO 3rd, Brooks PM, Christensen R, Conaghan PG, D'Agostino MA, de Wit M, Dueck AC, Goodman SM, Grosskleg S, Hill CL, Howell M, Mackie SL, Richards B, Shea B, Singh JA, Strand V, Tugwell P, Wells GA, Simon LS.

J Rheumatol. 2019 Aug;46(8):1053-1058. doi: 10.3899/jrheum.181123. Epub 2019 Jan 15.

PMID:
30647191
28.

Successful Methotrexate Treatment of Chronic Chikungunya Arthritis.

Amaral JK, Bingham CO 3rd, Schoen RT.

J Clin Rheumatol. 2018 Dec 5. doi: 10.1097/RHU.0000000000000943. [Epub ahead of print] No abstract available.

PMID:
30520824
29.

Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis.

Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA.

Rheumatology (Oxford). 2019 Mar 1;58(3):476-480. doi: 10.1093/rheumatology/key358.

30.

Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.

Darrah E, Giles JT, Davis RL, Naik P, Wang H, Konig MF, Cappelli LC, Bingham CO 3rd, Danoff SK, Andrade F.

Front Immunol. 2018 Nov 20;9:2696. doi: 10.3389/fimmu.2018.02696. eCollection 2018.

31.

Systematic Review and Meta-analysis: Mindfulness-Based Interventions for Rheumatoid Arthritis.

DiRenzo D, Crespo-Bosque M, Gould N, Finan P, Nanavati J, Bingham CO 3rd.

Curr Rheumatol Rep. 2018 Oct 18;20(12):75. doi: 10.1007/s11926-018-0787-4.

32.

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ, Shah AA, Sharfman WH, Cappelli LC.

J Immunother Cancer. 2018 Oct 11;6(1):104. doi: 10.1186/s40425-018-0417-8.

33.

Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study.

Mecoli CA, Park JK, Alexanderson H, Regardt M, Needham M, de Groot I, Sarver C, Lundberg IE, Shea B, de Visser M, Song YW, Bingham CO 3rd, Christopher-Stine L.

J Rheumatol. 2019 Jan;46(1):106-111. doi: 10.3899/jrheum.180353. Epub 2018 Sep 15.

PMID:
30219767
34.

Pain and Catastrophizing in Patients With Rheumatoid Arthritis: An Observational Cohort Study.

Cohen EM, Edwards RR, Bingham CO 3rd, Phillips K, Bolster MB, Moreland LW, Neogi T, Marder W, Wohlfahrt A, Clauw D, Lee YC.

J Clin Rheumatol. 2019 Aug;25(5):232-236. doi: 10.1097/RHU.0000000000000834.

PMID:
30035754
35.

A survey of Delphi panelists after core outcome set development revealed positive feedback and methods to facilitate panel member participation.

Turnbull AE, Dinglas VD, Friedman LA, Chessare CM, Sepúlveda KA, Bingham CO 3rd, Needham DM.

J Clin Epidemiol. 2018 Oct;102:99-106. doi: 10.1016/j.jclinepi.2018.06.007. Epub 2018 Jun 30.

PMID:
29966731
36.

Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study.

Park JK, Mecoli CA, Alexanderson H, Regardt M, Christopher-Stine L, Casal-Domínguez M, de Groot I, Sarver C, Lundberg IE, Bingham CO 3rd, Song YW.

J Rheumatol. 2018 Jul;45(7):1071. doi: 10.3899/jrheum.161252.C2. No abstract available.

PMID:
29961681
37.

Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug.

Wohlfahrt A, Bingham CO 3rd, Marder W, Phillips K, Bolster MB, Moreland LW, Zhang Z, Neogi T, Lee YC.

Arthritis Care Res (Hoboken). 2019 Apr;71(4):521-529. doi: 10.1002/acr.23617.

PMID:
29885039
38.

Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis.

Bartlett SJ, Gutierrez AK, Butanis A, Bykerk VP, Curtis JR, Ginsberg S, Leong AL, Lyddiatt A, Nowell WB, Orbai AM, Smith KC, Bingham CO 3rd.

Qual Life Res. 2018 Sep;27(9):2443-2451. doi: 10.1007/s11136-018-1880-x. Epub 2018 May 24.

39.

Phenotypic characterization of patients with rheumatologic manifestations of common variable immunodeficiency.

Gutierrez MJ, Sullivan KE, Fuleihan R; USIDNET Consortium, Bingham CO 3rd.

Semin Arthritis Rheum. 2018 Oct;48(2):318-326. doi: 10.1016/j.semarthrit.2018.02.013. Epub 2018 Feb 23.

40.

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.

Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO 3rd, Shah AA.

Semin Arthritis Rheum. 2018 Dec;48(3):553-557. doi: 10.1016/j.semarthrit.2018.02.011. Epub 2018 Mar 22.

41.

Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.

Cappelli LC, Konig MF, Gelber AC, Bingham CO 3rd, Darrah E.

Arthritis Res Ther. 2018 Mar 23;20(1):59. doi: 10.1186/s13075-018-1533-z.

42.

Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.

Albayda J, Bingham CO 3rd, Shah AA, Kelly RJ, Cappelli L.

Rheumatology (Oxford). 2018 Apr 1;57(4):760-762. doi: 10.1093/rheumatology/kex470. No abstract available.

43.

Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.

Bouta EM, Bell RD, Rahimi H, Xing L, Wood RW, Bingham CO 3rd, Ritchlin CT, Schwarz EM.

Nat Rev Rheumatol. 2018 Feb;14(2):94-106. doi: 10.1038/nrrheum.2017.205. Epub 2018 Jan 11. Review.

44.

Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study.

Park JK, Mecoli CA, Alexanderson H, Regardt M, Christopher-Stine L, Casal-Domínguez M, de Groot I, Sarver C, Lundberg IE, Bingham CO 3rd, Song YW.

J Rheumatol. 2017 Dec;44(12):1944. doi: 10.3899/jrheum.161252.C1. No abstract available.

PMID:
29196552
45.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

46.

Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.

Shi J, Darrah E, Sims GP, Mustelin T, Sampson K, Konig MF, Bingham CO 3rd, Rosen A, Andrade F.

Ann Rheum Dis. 2018 Jan;77(1):141-148. doi: 10.1136/annrheumdis-2017-211489. Epub 2017 Oct 25.

47.

Spontaneous Secretion of the Citrullination Enzyme PAD2 and Cell Surface Exposure of PAD4 by Neutrophils.

Zhou Y, Chen B, Mittereder N, Chaerkady R, Strain M, An LL, Rahman S, Ma W, Low CP, Chan D, Neal F, Bingham CO 3rd, Sampson K, Darrah E, Siegel RM, Hasni S, Andrade F, Vousden KA, Mustelin T, Sims GP.

Front Immunol. 2017 Sep 25;8:1200. doi: 10.3389/fimmu.2017.01200. eCollection 2017.

48.

Towards improving measurement of stiffness in rheumatology.

Orbai AM, Bingham CO 3rd.

Rheumatology (Oxford). 2018 Feb 1;57(2):206-208. doi: 10.1093/rheumatology/kex247. No abstract available.

PMID:
28968882
49.

Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016.

Morgan EM, Riebschleger MP, Horonjeff J, Consolaro A, Munro JE, Thornhill S, Beukelman T, Brunner HI, Creek EL, Harris JG, Horton DB, Lovell DJ, Mannion ML, Olson JC, Rahimi H, Gallo MC, Calandra S, Ravelli A, Ringold S, Shenoi S, Stinson J, Toupin-April K, Strand V, Bingham CO 3rd.

J Rheumatol. 2017 Dec;44(12):1884-1888. doi: 10.3899/jrheum.161389. Epub 2017 Aug 15.

50.

Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Bartlett SJ, Barbic SP, Bykerk VP, Choy EH, Alten R, Christensen R, den Broeder A, Fautrel B, Furst DE, Guillemin F, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Pohl C, Scholte Voshaar M, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2017 Oct;44(10):1536-1543. doi: 10.3899/jrheum.161145. Epub 2017 Aug 15.

Supplemental Content

Loading ...
Support Center